Kancera AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 3
- Market Cap
- -
- Website
- http://www.kancera.com
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 18
- Registration Number
- NCT06087289
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇳🇴Oslo University Hospital, Oslo, Norway
🇸🇪Skåne University Hospital, Lund, Sweden
Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 50
- Registration Number
- NCT06063343
- Locations
- 🇫🇮
Clinical Research Services Turku - CRST Oy, Turku, Finland
Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 23
- Registration Number
- NCT06030375
- Locations
- 🇫🇮
Clinical Research Services Turku (CRST), Turku, Finland
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 35
- Registration Number
- NCT06012565
- Locations
- 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇸🇪Capio St. Görans Hospital, Stockholm, Sweden
News
Kancera Receives FDA Fast Track Eligibility for KAND567 in Heart Attack Treatment
Kancera AB received positive FDA feedback on its clinical development program for KAND567 in ST-elevation myocardial infarction, with the agency agreeing the plan could support a marketing application.
Kancera Advances Cardiovascular Drug Pipeline with Recardio Partnership and FDA Engagement
Kancera AB has partnered with US biotech Recardio Inc. to create a cardiovascular disease-focused specialty care company, with Recardio licensing candidate drugs KAND567 and KAND145.
Kancera Pivots to Cardiovascular Disease, Prioritizing STEMI Treatment with KAND567 and KAND145
Kancera AB shifts focus to cardiovascular diseases, emphasizing the development of KAND567 and KAND145 for ST-elevation myocardial infarction (STEMI) treatment.